| Literature DB >> 34617243 |
Giorgos Sideris1, Vangelis Malamas2, George Tyrellis3, Pavlos Maragkoudakis3, Alexander Delides3, Thomas Nikolopoulos3.
Abstract
BACKGROUND: Peritonsillar abscess (PTA) is the most common deep neck infection, occurring as a consequence of bacterial acute tonsillitis or as a result of infection of the Weber glands, with frequent and life-threatening complications. AIM: To investigate several factors associated with complications and worse prognosis, such as defining the method of surgical drainage and treatment of a PTA which remains an area of controversy in the literatureEntities:
Keywords: Antibiotics; Complications; Deep neck infections; Drainage; Incision; Microbiology; Peritonsillar abscess
Mesh:
Substances:
Year: 2021 PMID: 34617243 PMCID: PMC8494509 DOI: 10.1007/s11845-021-02796-9
Source DB: PubMed Journal: Ir J Med Sci ISSN: 0021-1265 Impact factor: 2.089
Patients’ clinical profile, treatment, and outcome
| Adults ( | ||
|---|---|---|
| Demographics | Age (years) | 38.5 |
| Male | 386 | |
| Female | 215 | |
| Clinical signs | Pharyngalgia | 556 |
| Odynophagia | 322 | |
| Hot-potato voice | 112 | |
| Trismus | 365 | |
| Fever | 195 | |
| Malaise | 178 | |
| Lymphadenopathy | 92 | |
| Laboratory findings | WBC (× 103/µL) | 13.986 ± 3.782 |
| CRP (mg/L) | 82 ± 65.6 | |
| Comorbidities | 242 | |
| Treatment | ID + iv antibiotics | 561 |
| ID + oral antibiotics | 28 | |
| ATE | 12 | |
| MTA | 0 | |
| Complications | 68 | |
| Outcome | Survive | 600 |
| Death | 1 |
Microbiological findings
| Pathogen | No. of patients ( |
|---|---|
| Streptococcus pneumoniae | 11 |
| Streptococcus viridans | 13 |
| Group A streptococcus | 78 |
| Group B streptococcus | 32 |
| Staphylococcus species | 16 |
| Fusobacterium necrophorum | 27 |
| Anaerobic bacteria | 35 |
| Others | 21 |
| Mixed flora | 47 |
Comparison between inpatients (IP) with and without complications
| IP Group No complications ( | IP Group With complications ( | p-value | ||
|---|---|---|---|---|
| Age | Mean ± | 37.9 ± 14.5 (min: 17, max: 87) | 45.4 ± 15.5 (min: 17, max 86) | < 0.001 |
| 95% CI | 36.6–39.1 | 41.6–49.3 | ||
| Comorbidities | 195 | 42 | < 0.001 | |
| WBC | Mean ± | 13,779 ± 3690 | 15,395 ± 4450 | < 0.001 |
| 95% CI | 13,456–14,100 | 14,284–16,507 | ||
| CRP | Mean ± | 77.6 ± 60.8 | 125.5 ± 90 | < 0.001 |
| 95% CI | 72.2–82.8 | 103–148 | ||
| Hospitalization (days) | Mean ± | 2.96 ± 1.7 (min: 1, max: 7) | 6.53 ± 4.26 (min: 3, max: 21) | < 0.001 |
| 95% CI | 2.81–3.11 | 5.47–7.59 | ||
Comparison between patients that received iv (IP) and oral (OP) antibiotics
| IP Group ( | OP Group ( | p-value | ||
|---|---|---|---|---|
| Age | Mean ± | 38.7 ± 14.7 | 34.8 ± 8.4 | 0.16 |
| 95% CI | 37.5–39.9 | 31.52–38 | ||
| Comorbidities | 237 | 5 | 0.013 | |
| WBC | Mean ± | 14,960 ± 3812 | 14,526 ± 3118 | 0.44 |
| 95% CI | 13,647–14,272 | 13,318–15,735 | ||
| CRP | Mean ± | 82.8 ± 66.4 | 64.1 ± 42.8 | 0.14 |
| 95% CI | 77.4–88.3 | 47.5–80.7 | ||
| Complications | 64 | 4 | 0.612 | |